Traws Pharma, Inc. (TRAW) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Traws Pharma reported revenue of $2.8M, up 1134.5% from $226,000 the year before. Net income was $9.2M (a 328.7% net margin), or $0.82 per diluted share. Operating margin was -640.7%. Operating activities generated -$18.2M of cash, leaving -$20.8M of free cash flow. At fiscal year end, Traws Pharma held $10.6M in total assets against $11.2M in total liabilities.
Open the full interactive Traws Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
Traws Pharma Key Stats
| Share Price | $0.41 |
|---|---|
| Market Cap | $6.5M |
| P/E Ratio | 0.5 |
| 52-Week Range | $0.41 – $3.07 |
| Shares Outstanding | 15.9 million (basic, 2026 Q2) |
Traws Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $231,000 | $226,000 | $226,000 | $226,000 | $226,000 | $2.8M |
| Operating Income | -$25.0M | -$16.5M | -$19.6M | -$20.3M | -$142.4M | -$17.9M |
| Pre-Tax Income | -$25.2M | -$16.2M | -$19.0M | -$18.9M | -$166.5M | $9.2M |
| Income Tax | $4,000 | — | — | — | -$3,000 | — |
| Net Income | -$25.2M | -$16.2M | -$19.0M | -$18.9M | -$166.5M | $9.2M |
| Diluted EPS | -$52.50 | -$24.00 | -$22.75 | -$22.50 | -$35.21 | $0.82 |
Traws Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.0M | -$7.4M | -$7.1M | -$3.1M |
| Diluted EPS | -$0.34 | -$0.89 | -$0.53 | -$0.16 |
Traws Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $38.5M | $20.6M | — | — |
| Current Assets | $19.8M | $55.4M | $39.3M | $22.7M | $25.0M | $8.0M |
| Total Assets | $20.0M | $55.5M | $39.4M | $22.7M | $25.0M | $10.6M |
| Current Liabilities | $10.0M | $6.1M | $8.0M | $9.2M | $11.5M | $11.1M |
| Total Liabilities | $13.8M | $9.4M | $11.1M | $12.0M | $56.6M | $11.2M |
| Shareholders' Equity | $6.2M | $46.1M | $28.3M | $10.7M | -$31.6M | -$629,000 |
Traws Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$23.1M | -$19.5M | -$16.3M | -$17.9M | -$29.8M | -$18.2M |
| Cash From Investing | -$15,000 | — | — | -$14,000 | -$3.6M | -$2.6M |
| Cash From Financing | $19.4M | $55.6M | — | — | $34.0M | $3.2M |
| Free Cash Flow | -$23.1M | — | — | -$17.9M | -$29.8M | -$20.8M |
Figures from Traws Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Traws Pharma financials page for every line item.
Traws Pharma Company Profile
| Ticker | TRAW |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Newtown, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001130598 |
Frequently Asked Questions
What was Traws Pharma's revenue in fiscal 2025?
Traws Pharma (TRAW) reported revenue of $2.8M for fiscal 2025.
What is Traws Pharma's annual revenue history?
Traws Pharma's annual revenue by fiscal year: 2020: $231,000; 2021: $226,000; 2022: $226,000; 2023: $226,000; 2024: $226,000; 2025: $2.8M.
What was Traws Pharma's net income in fiscal 2025?
Traws Pharma reported net income of $9.2M for fiscal 2025.
What was Traws Pharma's earnings per share (EPS) in fiscal 2025?
Traws Pharma's diluted EPS was $0.82 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Traws Pharma generate in fiscal 2025?
Traws Pharma generated -$20.8M of free cash flow in fiscal 2025.
What was Traws Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Traws Pharma reported revenue of $0.
How many shares of Traws Pharma are outstanding?
Traws Pharma reported a weighted average of 15.9 million basic shares outstanding in 2026 Q2.
What is Traws Pharma's market cap?
Based on its latest closing price, Traws Pharma (TRAW) has a market capitalization of about $6.5M.
When does Traws Pharma's fiscal year end?
Traws Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is Traws Pharma headquartered?
Traws Pharma lists its business address in Newtown, Pennsylvania in its SEC filings.